Why It Matters
Genentech disclosed $1.81 million in lobbying expenditures for the second quarter of 2026, marking a significant jump from its modest $378,000 in the first quarter. The pharmaceutical lobbying effort reflects intensified activity as the company navigates a shifting landscape around drug pricing and Medicare negotiations.
The company's LDA filing provided limited transparency on its specific legislative targets, citing general issue areas as budget/appropriations, copyright/patent, health issues, immigration, manufacturing, medical/disease research, Medicare/Medicaid, pharmacy, taxation, and trade.
Genentech is operating in an environment where the Inflation Reduction Act's Medicare Drug Price Negotiation Program went live Jan. 1, 2026, with prices for the first 10 drugs now in effect. The Centers for Medicare & Medicaid Services is actively negotiating prices for 15 more drugs under the program for 2027 implementation.
By the Numbers
The company also retained external firms. OGR lobbied on behalf of Genentech for $60,000 focused on public health preparedness issues in the prior quarter. Forbes Tate Partners registered for $50,000 in the first quarter, covering intellectual property, patent, Medicare and Medicaid, 340B drug pricing, and tax-related issues.
Compared to recent quarters, Genentech's spending more than tripled from the first quarter's $378,000. Similarly, last year's second quarter saw $1.94 million in disclosure.
The Bottom Line
Genentech's pharmaceutical lobbying activity signals sustained focus on core policy areas even as drug pricing pressure intensifies at the federal level. The blank specific issues field in the second quarter LDA filing limits transparency into exactly which bills or proposals drew the company's attention during the quarter.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article